Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Wednesday 28 May, 2014

GlaxoSmithKline PLC

Serious Fraud Office Investigation

RNS Number : 1700I
GlaxoSmithKline PLC
27 May 2014
 

 

Issued: 27 May 2014, London UK - LSE announcement

 

Serious Fraud Office Investigation

 

 

GlaxoSmithKline plc (LSE/NYSE: GSK) has today been informed by the UK's Serious Fraud Office (SFO) that it has opened a formal criminal investigation into the Group's commercial practices.

GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO.

 

 

V A Whyte

Company Secretary

27 May 2014

 

 

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

 

 

GSK enquiries:




UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)


Simon Steel

+44 (0) 20 8047 5502

(London)





US Media enquiries:

Stephen Rea

+1 215 751 4394

(Philadelphia)









Analyst/Investor enquiries:

Ziba Shamsi

+44 (0) 20 8047 5543

(London)


Kirsty Collins (SRI & CG)

+44 (0) 20 8047 5534

(London)


Tom Curry

+ 1 215 751 5419

(Philadelphia)


Gary Davies

+44 (0) 20 8047 5503

(London)


James Dodwell

+44 (0) 20 8047 2406

(London)


Jeff McLaughlin

+1 215 751 7002

(Philadelphia)


Lucy Singah

+44 (0) 20 8047 2248

(London)

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEUFWWFLSELI